Phil Ferneau

Investor at Ankyra Therapeutics

Hanover, New Hampshire

Overview

Phil Ferneau is the Co-founder and Managing Partner of Borealis Ventures in Hanover, New Hampshire, with a focus on venture capital and entrepreneurship. With a background in investments and product development, he has successfully invested in a range of companies including Ankyra and Orbit Discovery, showcasing his expertise in seed and Series B funding. Ferneau's career highlights include his role as a Board Director and Investor at Compass Therapeutics LLC, as well as his investment in companies like Ankyra (Series B) and Orbit Discovery (Seed), demonstrating his strategic approach to supporting and growing innovative startups in sectors such as Digital Health and Health IT.

Work Experience

Borealis Ventures

Co-Founder and Managing Partner
2002 - Current
Early-stage healthcare venture capital firm, with a focus on life science platforms, digital health, and animal health opportunities.

Borealis Ventures partners with early-stage entrepreneurs to build market-defining companies in information technology and life sciences.

borealisventures.com

Compass Therapeutics LLC

Board Director and Investor
2014
Antibody therapeutics to treat cancer (Nasdaq: CMPX)

Compass Therapeutics is a biopharmaceutical company that focuses on drugging the immune system to treat human diseases.

Raised $381,512,210.00 from Dafna Capital Management, Vivo Capital, Monashee Investment Management, Braidwell, OrbiMed, Adage Capital Management, Enavate Sciences and Janus Henderson Investors.

compasstherapeutics.com

Ankyra Therapeutics

Board Director and Investor
2021
Intratumoral immunotherapy.

Ankyra is a biotech company developing anchored immunotherapy for cancer treatments.

Raised $59,500,000.00 from Sands Capital Ventures, Google Ventures, Borealis Ventures, Mithril Capital Management, Fidelity, Polaris Partners and Spring Mountain Capital.

ankyratx.com

Triveni Bio

Investor and Former Board Director
2020
Genetics-informed antibody therapies for I&I disorders.

Triveni Bio is a a biotech company that develops functional antibodies targeting immunological and inflammatory disorders.

Raised $207,000,000.00 from Goldman Sachs Alternatives, Cormorant Asset Management, Atlas Venture, Invus, Fidelity, OrbiMed, Deep Track Capital and Viking Global Investors.

triveni.bio